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Abstract
Background: Inhibition of intestinal peristalsis is a major side effect of opioid analgesics. Although
tramadol is an opioid-like analgesic, its effect on gut motility is little known. Therefore, the effect
of (+)-tramadol, (-)-tramadol and the major metabolite O-desmethyltramadol on intestinal
peristalsis in vitro and their mechanisms of action were examined. Distension-induced peristalsis
was recorded in fluid-perfused segments of the guinea pig small intestine. The intraluminal
peristaltic pressure threshold (PPT) was used to quantify the motor effects of extraserosally
administered drugs.
Results:  Racemic tramadol, its (+)- and (-)-enantiomers and the major metabolite O-
desmethyltramadol (0.1 – 100 µM) concentration-dependently increased PPT until peristalsis was
transiently or persistently abolished. The rank order of potency was (-)-tramadol < (+)-tramadol
<O-desmethyltramadol. The peristaltic motor inhibition caused by (+)- and (-)-tramadol was
markedly and that of O-desmethyltramadol nearly completely prevented by naloxone, but left
unaltered by the 5-hydroxytryptamine receptor antagonists methysergide plus tropisetron. The
adrenoceptor antagonists prazosin plus yohimbine reduced the effect of (+)- and (-)-tramadol but
not that of O-desmethyltramadol.
Conclusion:  The results show that the metabolite O-desmethyltramadol is more potent in
inhibiting peristalsis than its parent compound. The action of all tramadol forms depends on opioid
receptors, and that of (+)- and (-)-tramadol also involves adrenoceptors.
Background
Potent analgesics such as the opioids are required to treat
moderate to severe acute and chronic pain. The use of opi-
oids is accompanied by serious side effects such as inhibi-
tion of gastrointestinal motility [1]. As a result, several
strategies to prevent opioid bowel dysfunction have been
envisaged. In particular, opioid-like compounds with a
reduced impact on intestinal function and opioid receptor
antagonists with a peripherally restricted site of action
have been developed [2,3]. Tramadol is a centrally acting
synthetic 4-phenylpiperidine analogue of codeine, which
has become available as an analgesic for the treatment of
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moderate to severe pain [4]. Its efficacy has been con-
firmed in postoperative [5,6], neuropathic [7,8] and oste-
oarthritic pain [9,10] as well as in patients suffering from
chronic pancreatitis [11]. The analgesic potency of trama-
dol appears to depend on the pain state under treatment
and has been described as similar [12] or, in the case of
pancreatitis, even superior to that of morphine [11]. How-
ever, there is controversial information as to whether tra-
madol has an inhibitory action on gut motility in
humans, and there is little known as to which mecha-
nisms underlie such an effect [9,12].
The analgesic effect of tramadol is mediated through two
distinct but complementary mechanisms of action. It acts
as an opioid agonist with selectivity for the µ-opioid
receptor and binds weakly to the κ- and δ-opioid receptor
[13]. Tramadol is extensively metabolised in the liver, and
the O-desmethyl metabolite displays a 200-fold higher
affinity for opioid receptors than the parent drug [4]. The
analgesic and antinociceptive effects of tramadol are only
partially antagonised by the opioid antagonist naloxone,
which suggests that nonopioid mechanisms are also
involved [4,13]. Thus, at the same concentrations at
which it binds to opioid receptors, tramadol acts on
monoamine systems to inhibit the reuptake of norepine-
phrine and serotonin [13-15]. Furthermore, the (+)- and
(-)-enantiomers differentially contribute to the analgesic
effect of racemic tramadol which is the clinically used
form of the drug. The (+)-enantiomer has a higher affinity
for the µ-receptor and is a more effective inhibitor of 5-HT
reuptake, whereas the (-)-enantiomer is a more effective
inhibitor of norepinephrine reuptake and increases nore-
pinephrine release by autoreceptor activation.
In view of these findings the current study pursued three
aims. The first goal was to explore whether tramadol is
able to inhibit intestinal peristalsis and to characterize this
action in quantitative terms. Since tramadol is available in
the form of the (+) and (-) enantiomer and the compound
is metabolised to the active metabolite O-desmethyltra-
madol [16], the second aim was to compare (+)- and (-)-
tramadol as well as O-desmethyltramadol in their potency
and efficacy to depress intestinal peristalsis. The third aim
of the study was to explore whether any effect of tramadol
on intestinal peristalsis is exclusively due to activation of
opioid receptors or whether there is also an opioid recep-
tor-independent component of action. Further experi-
ments were designed to differentiate between an
involvement of 5-hydroxytryptamine (5-HT) receptors
and adrenoceptors in the opioid receptor-independent
inhibition of peristalsis due to tramadol.
Results
Under control conditions regular peristaltic contractions
were recorded that stayed constant in all experiments and
were not influenced by the addition of vehicle (Tyrode's
solution, data not shown). A pilot study showed that
racemic tramadol (1–10–30–100 µM) administered to
the organ bath in a cumulative manner increased PPT in a
concentration-dependent fashion (Figs 1A and 2). Peri-
stalsis was totally abolished by 100 µM racemic tramadol
(Fig. 1A) in 5 of 6 segments.
Addition of (+)- and (-)-tramadol to the organ bath led to
an increase of PPT and compromised ileal peristaltic con-
tractions in a concentration-related manner. While
Tyrode's solution as well as 1 µM (+)-tramadol and (-)-tra-
madol did not affect peristalsis, PPT was transiently
enhanced by 10 µM (+)-tramadol (Fig. 1B, 3A). A more
pronounced increase of PPT was caused by 30 µM (+)-
and (-)-tramadol (mean ∆ PPT 118.8 ± 31.3 Pa and 77.1
± 20.9 Pa, respectively). An increase in the frequency of
peristaltic waves was also observed. Peristalsis completely
ceased with a latency of 8.3 ± 4.1 min and a duration of
9.7 ± 0.4 min in two segments exposed to 30 µM (+)-tra-
madol. Regular peristalsis reoccurred in these two seg-
ments, however, with a slightly higher PPT than in the
initial control period. Administration of 100 µM (+)- and
(-)-tramadol abolished peristalsis after 11.2 ± 4.3 min and
5.3 ± 0.8 min, respectively, in all segments tested (Fig.
1C). In 5 of 6 segments inhibited by 100 µM (-)-tramadol
spontaneous ileal contractions recovered 9.2 ± 3.0 min
with intermittend periods of disturbed motility. The mean
increase of PPT due to 100 µM (+)-tramadol was more
prolonged than that due to 100 µM (-)-tramadol (Figs 3A
and 3B).
O-Desmethyltramadol had a stronger inhibitory effect on
peristalsis than the (+)- and (-)-tramadol enantiomers.
The lowest concentrations of 0.1 and 1 µM O-desmethyl-
tramadol did not affect the PPT, but peristalsis was already
inhibited by 10 µM O-desmethyltramadol for 18.3 min in
one segment. The mean increase of PPT due to 10 µM O-
desmethyltramadol during the observation period of 60
min was 91.8 ± 32.9 Pa (Fig. 3C). At 30 µM, O-desmeth-
yltramadol abolished peristalsis transiently in 3 of 6 seg-
ments after a latency of 3.6 ± 1 min and on average
increased PPT by 239.1 ± 51.9 Pa in all segments tested
during the first 20 min post-administration (Fig. 3C). Per-
istalsis was completely blocked by 100 µM O-desmethyl-
tramadol in all segments, an effect that took place in less
than 4 min after addition of the drug. Inhibition of peri-
stalsis manifested itself either as complete absence of any
motor activity or as stationary high-frequency oscillations
of intraluminal pressure, which did not propel the intra-
luminal contents.
The inhibitory potency of (-)-tramadol to impair intesti-
nal peristalsis (EC50 = 73 µM) was lower than that of (+)-
tramadol (EC50 = 53 µM), and the metabolite O-desmeth-BMC Pharmacology 2007, 7:5 http://www.biomedcentral.com/1471-2210/7/5
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Original recordings of the effect of racemic and (+)-tramadol on peristalsis Figure 1
Original recordings of the effect of racemic and (+)-tramadol on peristalsis. (A) Luminal perfusion of isolated seg-
ments of the guinea pig small intestine slowly increased the intraluminal pressure; when the peristaltic pressure threshold (PPT, 
marked by an arrow in the inset of A was reached, a peristaltic wave shown as a spike-like increase of intraluminal pressure 
was triggered. Increasing concentrations of racemic tramadol were cumulatively added to the bath. Peristaltic activity was con-
stant during a control period and remained uninfluenced by 1 µM racemic tramadol. PPT was concentration-dependently 
increased by 10 and 30 µM racemic tramadol and peristalsis was completely abolished by 100 µM of the drug. (B) The concen-
tration of 30 µM (+)-tramadol added singly to the bath caused an increase in PPT and peristalsis ceased for about 10 min. 
Thereafter peristaltic contractions returned, however, with a markedly higher PPT. (C) Peristaltic contractions were com-
pletely abolished by 100 µM (+)-tramadol added singly to the bath, so that despite an intraluminal pressure of 400 Pa no peri-
stalsis took place. The high-frequency oscillations of intraluminal pressure in the later part of the tracing represent 
uncoordinated gut wall motions without any propulsion of the intraluminal contents.
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yltramadol with an EC50 = 13.6 µM was more potent than
either enantiomer (Fig. 4).
Pre-treatment with the pan-opioid receptor antagonist
naloxone (0.5 µM) prevented the inhibition of intestinal
peristalsis caused by tramadol. The reduction of the max-
imum inhibitory effect of 100 µM (-)-tramadol, 100 µM
(+)-tramadol and 100 µM O-desmethyltramadol on PPT
was 70 %, 80 % and 90 %, respectively (Fig. 5).
Pre-treatment with a combination of the 5-HT receptor
antagonists methysergide plus tropisetron did not affect
the increase of PPT caused by the equieffective concentra-
tions of 30 µM (-)-tramadol, 30 µM (+)-tramadol and 10
µM O-desmethyltramadol (Fig. 6). In contrast, the inhib-
itory effect of 30 µM (+)-tramadol and 30 µM (-)-trama-
dol was significantly reduced by the combination of the
α1- and α2- adrenoceptor antagonists prazosin and
yohimbine (Fig. 7), while the PPT increase due to 10 µM
O-desmethyltramadol remained unchanged.
As summarized in Table 1, the receptor antagonists used
here caused only minimal changes of PPT by themselves.
PPT slightly decreased due to naloxone and slightly
increased due to the 5-HT receptor antagonists, with mean
PPT changes lower than 15 Pa.
Discussion
The (+)- and (-)-enantiomers of tramadol and its major
metabolite O-desmethyltramadol impaired intestinal per-
istalsis in a concentration-dependent manner as deduced
from an increase in the peristaltic pressure threshold. The
increase in the frequency of the peristaltic waves which
was also seen following exposure to submaximal concen-
trations of tramadol is likely to reflect an impairment of
the peristaltic contractions resulting in incomplete empty-
ing of the intestinal segments. O-desmethyltramadol was
more potent than the parent compounds (+)- and (-)-tra-
madol. Overall the inhibitory potency of (+)-tramadol, (-
)-tramadol and O-desmethyltramadol was considerably
lower than that of the classical opioids such as fentanyl,
sufentanil and morphine, which have an EC50  in the
nanomolar range as tested in the same experimental in
vitro setup [18,20]. Codeine, the parent molecule of tra-
madol has an EC50 of 21 µM, which is in the same order
of magnitude as O-desmethyltramadol (EC50 = 13.5 µM)
[18]. The stronger inhibitory effect on gut motility of O-
desmethyltramadol is in line with its more potent analge-
sic capacity compared to that of both enantiomers [4].
The current data are of clinical relevance, given that the
ability of tramadol to inhibit gastrointestinal motility in
humans is controversial. In one study tramadol was found
to slow colonic transit time to a small extent in healthy
volunteers, but had no effect on upper gastrointestinal
motility [21]. Another study found tramadol to have a
measurable but smaller inhibitory effect on gastric empty-
ing than morphine and codeine [22]. In patients suffering
from chronic pancreatitis, orocecal transit time remained
unchanged after 5 days of tramadol treatment, but
increased with morphine [11]. Gastrointestinal motility
was also assessed after abdominal hysterectomies in
patients receiving 48-h infusions of morphine or trama-
dol postoperatively in a randomized and double-blind
fashion [12]. Orocecal and colonic transit times increased
after infusion of both morphine and tramadol, but gastric
emptying was prolonged only with morphine. In rand-
omized and placebo-controlled studies of patients with
diabetic neuropathy and polyneuropathy, who received
210 mg or 200–400 mg tramadol per day with good anal-
gesic benefit, a constipating effect of tramadol was
observed [7,8]. Studies in patients suffering from cancer
have shown that tramadol has a constipating effect,
which, however, is less severe than that of morphine [23].
The present results show that tramadol has the potential
to inhibit peristalsis in a concentration-dependent man-
ner.
Another aim of this study was to explore the mechanisms
underlying the inhibitory action of the tramadol enanti-
omers and O-desmethyltramadol on intestinal peristalsis.
The increase of PPT due to tramadol could to a large extent
Concentration-response relationship for the increase in PPT  (Pa) caused by racemic tramadol (1–100 µM) Figure 2
Concentration-response relationship for the increase 
in PPT (Pa) caused by racemic tramadol (1–100 µM). 
The symbols represent the mean values ± SEM of PPT 
recorded from 6 intestinal segments.
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be prevented by the opioid receptor antagonist naloxone,
and the inhibition due to O-desmethyltramadol was in
fact attenuated by 90 %. This confirms that most of the
inhibitory effect of tramadol on gut motility depends on
opioid receptor activation, whereas its analgesic effect
could be antagonized with naloxone by 30 % only [24]. A
major part of the tramadol-induced analgesia is mediated
by reuptake inhibition and release of serotonin and nore-
pinephrine [13-15]. Of these two transmitters, only nore-
pinephrine seems to play an appreciable role in the
inhibitory action of (+)- and (-)-tramadol on peristalsis,
since the combination of the α1- and α2- adrenoceptor
antagonists prazosin plus yohimbine diminished the
inhibitory effect of both enantiomers to a significant
extent. The localization of these adrenoceptors to the var-
ious components of the peristaltic nerve-muscle circuitry
underlying peristalsis awaits to be addressed. In contrast,
peristaltic motor inhibition due to the metabolite O-des-
methyltramadol remained unchanged by α1- and α2-
adrenoceptor antagonism. The 5-HT receptor antagonists
methysergide plus tropisetron (antagonists at 5-HT1, 5-
HT2 and 5-HT7 as well as 5-HT3 receptors) did not signifi-
Concentration- and time-related effect of various forms of tramadol to increase PPT Figure 3
Concentration- and time-related effect of various forms of tramadol to increase PPT. (A) (+)-tramadol (1 – 100 
µM), (B) (-)-tramadol (1 – 100 µM), and (C) O-desmethyltramadol (0.1–100 µM) increased PPT in a concentration dependent 
manner. The time of administration of (+)-tramadol, (-)-tramadol and O-desmethyltramadol is indicated by an arrow. The sym-
bols represent the mean values of PPT recorded from 6 segments at consecutive 5 min intervals; the positive error bars show 
the standard error of the mean (SEM).
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cantly affect the motor action of (+)-tramadol, (-)-trama-
dol and O-desmethyltramadol. It was beyond the scope of
this study to analyze the possible implication of all 5-HT
receptor subtypes present in the gastrointestinal tract. In
agreement with its analgesic action, the inhibition of per-
istalsis due to O-desmethyltramadol is more pronounced
than that due to (+)- and (-)-tramadol and the inhibitory
motor action of O-desmethyltramadol appears to be
solely mediated by opioid receptor mechanisms.
The present data raise the important question as to how
the concentrations of (+)-tramadol, (-)-tramadol and O-
desmethyltramadol found to inhibit peristalsis in the in
vitro setting compared with the concentrations of trama-
dol, its enantiomers and metabolite that are analgesic
under clinical conditions in vivo. In this respect, the evalu-
ation of drug effects on in vitro organ bath preparations
has both advantages and limitations. In vitro, environ-
mental conditions such as temperature, oxygenation,
composition of the bath solution and drug concentration
can be kept constant in a controlled manner. However,
protein binding, distribution, metabolism and excretion
of drugs cannot be modelled in vitro. As a consequence,
the pharmacokinetic and pharmacodynamic conditions
of drug action differ considerably between the in vitro and
in vivo settings. In this context it is evident that our in vitro
preparation has the advantages (i) to reveal effects of low
drug concentrations on peristalsis, (ii) to describe these
effects in quantitative terms, (iii) to confirm that the
observed drug effects arise exclusively from interaction
with intestinal structures and mechanisms and (iv) to
reveal that the observed drug effects are independent of
changes in local, regional and systemic perfusion and
other hemodynamic parameters.
In systematic pharmacokinetic studies, plasma concentra-
tions of tramadol, its enantiomers and O-desmethyltra-
madol have been found to show considerable
Concentration-response relationships for the increase in PPT (Pa) caused by various forms of tramadol Figure 4
Concentration-response relationships for the increase in PPT (Pa) caused by various forms of tramadol. The 
concentration-response relationships for the increase in PPT (Pa) caused by (-)-tramadol, (+)-tramadol (1–100 µM) and O-des-
methyltramadol (0.1–100 µM) is compared to that seen after vehicle (Tyrode's solution) administration. The symbols repre-
sent means with SEM, n = 6 segments.
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interindividual variations [25-28]. Depending on the
study design the minimum effective concentration of tra-
madol to cause analgesia is in the range of 0.1 – 10 µM
[25,28]. Compared with the concentrations that inhibited
intestinal peristalsis in the current study, these figures sug-
gest that clinically relevant plasma concentrations of tra-
madol, its enantiomers and metabolite will gradually
impair intestinal peristalsis in a concentration-dependent
manner. However, the concentrations of (+)-tramadol, (-
)-tramadol and O-desmethyltramadol (100 µM) that
completely block peristalsis are unlikely to be reached
under routine clinical conditions.
Conclusion
Racemic tramadol, its (+) and (-) enantiomers as well as
their major metabolite O-desmethyltramadol inhibit per-
istalsis in the guinea pig small intestine at micromolar
concentrations. Since the clinically relevant plasma con-
centrations of tramadol are below those that abolish per-
istalsis in the guinea pig small bowel, it is tentatively
concluded that tramadol is an alternative to classical opi-
ate therapy as it has a more favourable profile of gastroin-
testinal adverse effects.
Methods
Animals
After obtaining approval from the Animal Care and Use
Committee at the Government of Lower Franconia,
Wuerzburg, Germany, adult guinea-pigs (BFA strain,
Charles-River Wiga, Sulzfeld, Germany) of either sex
weighing between 340 and 470 g were stunned and bled
via the carotid arteries. The guinea pigs were not used
before 3 days after their arrival at the animal care facility.
Naloxone (Nalox) attenuates the inhibitory effect of tramadol on peristalsis Figure 5
Naloxone (Nalox) attenuates the inhibitory effect of tramadol on peristalsis. The increase in PPT due to 100 µM (-
)-tramadol, (+)-tramadol and O-desmethyltramadol was significantly reduced by pre-treatment with the pan-opioid receptor 
antagonist naloxone (0.5 µM). The bars represent means with SEM, n = 6 segments, *P < 0.05 as compared with vehicle 
(Tyrode's solution).
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They were housed in standard cages within the depart-
mental animal house and received standard guinea-pig
food and water ad libitum until the time of the experi-
ment.
Experimental and recording protocol
The experimental and recording protocol has been
described in detail [17]. In brief, the jejunum and ileum
were excised, flushed of luminal contents and placed in
Tyrode's solution at room temperature, gassed with 95%
O2 and 5% CO2, until used. For studying peristalsis, the
distal small intestine (at least 10 cm proximal to the ile-
ocecal valve) was divided into segments, each being
approximately 8 to 10 cm long. Five intestinal segments
were set up in parallel in silanized glass organ baths con-
taining 30 mL of Tyrode's solution at 37°C. The oral end
of the intestinal segment was tied to an inflow cannula,
which permitted the continuous infusion of prewarmed
Tyrode's solution at a flow rate of 0.5 mL min-1. The abo-
ral end of the segment was attached to an intermediate
tubing fixed with a T piece. One arm of the T piece was
connected to a pressure transducer for recording of the
intraluminal pressure and the other arm of the T piece was
fitted with a vertical outlet tubing that ended 4 cm above
the fluid level of the organ bath. This arrangement made
emptying of the intestinal segment possible when peri-
staltic contractions raised the intraluminal pressure above
400 Pascal (Pa). When the intraluminal pressure reached
a threshold (peristaltic pressure threshold, PPT, inset of
Fig. 1A), an aborally moving wave of peristaltic contrac-
tion was triggered and the emptying phase of peristalsis
initiated. The wave of circular muscle contraction, meas-
ured as a spike-like increase in intraluminal pressure, pro-
pelled the intraluminal fluid to leave the system via the
The inhibitory effect of tramadol on peristalsis remained unaffected by 5-HT receptor antagonists (5-HT Antagon) Figure 6
The inhibitory effect of tramadol on peristalsis remained unaffected by 5-HT receptor antagonists (5-HT Anta-
gon). The increase in PPT due to the submaximally effective concentrations of 30 µM (-)-tramadol, (+)-tramadol and O-des-
methyltramadol was not reduced by pre-treatment with the combination of the 5-HT receptor antagonists methysergide (1 
µM) plus tropisetron (1 µM). The bars represent means with SEM, n = 6 – 8 segments. There was no significant difference rel-
ative to the values measured after vehicle (Tyrode's solution) administration.
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outlet tubing and thus caused emptying of the segment.
The intraluminal pressure at the aboral end of the seg-
ments was measured with a pressure transducer whose sig-
nal was, via an analog/digital converter, fed into a
personal computer and recorded simultaneously on a
pen-recorder.
The preparations were allowed to equilibrate in the organ
bath for a period of 30 min. Thereafter the bath fluid was
renewed and peristaltic motility initiated by intraluminal
perfusion of the segments. After basal peristaltic activity
had been recorded for at least 30 min, the drugs to be
tested were administered to the bath, i.e., to the serosal
surface of the intestinal segments. All vehicle solutions
used in this study were tested separately to ensure that
they were devoid of any influence on peristaltic activity.
Pilot experiments were designed to explore the overall
action of racemic tramadol on intestinal peristalsis. For
this purpose, six ileal segments from six different guinea
pigs were exposed to racemic tramadol which was added
to the organ bath in a cumulative manner at concentra-
tions of 1–10–30–100 µM in intervals of 20 min.
In separate series of experiments (i-iii) the effects of the
two enantiomers (+)- and (-)-tramadol and of the major
metabolite  O-desmethyltramadol on gut motility were
Inhibitory effect of tramadol on peristalsis after pre-treatment with adrenoceptor antagonists (Adreno Antagon) Figure 7
Inhibitory effect of tramadol on peristalsis after pre-treatment with adrenoceptor antagonists (Adreno Anta-
gon). The increase in PPT due to the submaximally effective concentrations of 30 µM (-)-tramadol and 30 µM (+)-tramadol 
was significantly reduced by the combination of prazosin (α1-adrenoceptor antagonist, 1 µM) plus yohimbine (α2-adrenoceptor 
antagonist, 1 µM), whereas the effect of 10 µM O-desmethyltramadol on PPT was not affected. The bars represent means with 
SEM, n = 6 segments. *P < 0.05 as compared with vehicle (Tyrode's solution).
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Table 1: Change of PPT due to Vehicle and Various Antagonists 
during a Period of 20 min
∆ PPT (Pa)
Vehicle (Tyrode's solution) n = 54 0.31 ± 1.9
Naloxone (0.5 µM) n = 18 -10.4 ± 1.6
Methysergide (1 µM) + tropisetron (1 µM) n = 18 13.4 ± 2.5
Yohimbine (1 µM) + prazosin (1 µM) n = 18 3.0 ± 2.0
Data represent means ± SEMBMC Pharmacology 2007, 7:5 http://www.biomedcentral.com/1471-2210/7/5
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investigated in a more detailed manner. Each concentra-
tion of (+)-tramadol, (-)-tramadol (1,10,30,100 µM) and
O-desmethyltramadol (0.1,1,10,30,100 µM) was tested
on six segments from six different guinea pigs and each
segment was exposed to only one drug concentration. The
peristaltic contractions were recorded for 60 min after
addition of the drug. To explore whether (+)-tramadol, (-
)-tramadol and O-desmethyltramadol exert their inhibi-
tory action on gut motility through (iv) activation of opi-
oid receptors or interference with the reuptake of (v) 5-HT
and (vi) norepinephrine the following experiments were
performed: (iv) Naloxone (0.5 µM) was given into the
organ bath 20 min prior to the addition of 100 µM (+)-
tramadol, (-)-tramadol and O-desmethyltramadol. The
combination of (v) 1 µM methysergide (nonselective
antagonist at 5-HT receptors, predominantly 5-HT1, 5-
HT2, 5-HT7) plus 1 µM tropisetron (selective antagonist at
5-HT3 receptors) or of (vi) 1 µM prazosin (antagonist at
α1-adrenoceptors) plus 1 µM yohimbine (antagonist at
α2-adrenoceptors) was added to the organ bath 20 min
prior to administration of the submaximally effective con-
centrations of 30 µM (+)-tramadol, (-)-tramadol and 10
µM  O-desmethyltramadol. The effect of tramadol
recorded in the presence of the antagonists was compared
with that seen in the presence of vehicle (Tyrode's solu-
tion).
Drugs
(+)-Tramadol, (-)-tramadol and O-desmethyltramadol
were supplied by Gruenenthal (Stollberg, Germany) and
tropisetron was purchased from Novartis Pharma Ltd.
(Nuernberg, Germany). All other chemicals were from
commercial sources and of the highest purity available.
The chemicals were dissolved in sterile water, and stock
solutions were further diluted with Tyrode's solution
before use. The composition of the Tyrode's solution was
(in mM): NaCl 136.9, KCl 2.7, CaCl2 1.8, MgCl2 1.0,
NaHCO3 11.9 and NaH2PO4 0.4 and glucose 5.6.
Calculation of data
PPT was used to quantify drug effects on peristalsis. After
regular peristaltic contractions had been recorded for at
least 20 min, the PPT of the last peristaltic wave immedi-
ately before drug addition was taken as baseline. Follow-
ing drug administration the PPT of the last complete
peristaltic wave within consecutive 5 min periods (i.e., 5,
10, 15 and further up to 60 min post-administration) was
calculated. Inhibition of peristalsis was reflected by an
increase in PPT, and abolition manifested itself in a lack
of propulsive motility in spite of an intraluminal pressure
of 400 Pa as set by the position of the outlet tubing.
Although in this case PPT exceeded 400 Pa, abolition of
peristalsis was expressed quantitatively by assigning PPT a
value of 400 Pa in order to obtain numerical results suita-
ble for further statistical evaluation [17,18].
In order to obtain the net increase of PPT caused by (+)-,
(-)-tramadol and O-desmethyltramadol, the baseline PPT
was subtracted from the respective PPT values recorded in
the presence of (+)-tramadol, (-)-tramadol and O-des-
methyltramadol.
Statistics
The data were analysed for normal distribution using the
Kolmogorov-Smirnov-Test. Since normality was con-
firmed, all quantitative data are presented as mean ± SEM
(standard error of the mean). Significance was evaluated
using ANOVA and post hoc Student-Newman-Keuls or Stu-
dent t test as appropriate for a level of P < 0.05 (Sigma Stat
for Windows, version 2.03, SPSS Inc., Chicago, IL). The
50% effective concentration value (EC50 value) for (+)-tra-
madol, (-)-tramadol and O-desmethyltramadol was calcu-
lated by the method of Tallarida and Murray [19].
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